In cancer cells, combination of RAS(ON) G12C-selective and SHP2 inhibitors prevents MAPK reactivation, which extends the reversion of immune evasive mechanisms driven by oncogenic KRAS, such as secretion of immune evasive cytokines and inhibition of IFN responses. The gene discussed is KRAS; the disease is cancer.